Back to Search
Start Over
Imatinib withdrawal syndrome and longer duration of imatinib have aclose association with a lower molecular relapse after treatmentdiscontinuation: the KID study
- Source :
- HAEMATOLOGICA(101): 6
- Publication Year :
- 2016
-
Abstract
- The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as ≥ 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse. (Trial registered at ClinicalTrials.gov: NCT01564836).
- Subjects :
- Adult
Male
Musculoskeletal pain
medicine.medical_specialty
Neoplasm, Residual
Time Factors
Fusion Proteins, bcr-abl
Antineoplastic Agents
Polymerase Chain Reaction
Gastroenterology
Article
03 medical and health sciences
0302 clinical medicine
Recurrence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Internal medicine
hemic and lymphatic diseases
medicine
Humans
Protein Kinase Inhibitors
neoplasms
Aged
Aged, 80 and over
business.industry
Imatinib
Hematology
Middle Aged
Prognosis
medicine.disease
Surgery
Discontinuation
Leukemia
Treatment Outcome
Imatinib mesylate
030220 oncology & carcinogenesis
Major Molecular Response
Retreatment
Imatinib Mesylate
Female
Withdrawal syndrome
business
After treatment
Follow-Up Studies
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- HAEMATOLOGICA(101): 6
- Accession number :
- edsair.doi.dedup.....c5cafecbf0a4a5eb54c4bc31e6239366